Back to Results
First PageMeta Content
Clinical research / Lysosomal storage diseases / Glycogen storage disease type II / Hepatology / Enzyme replacement therapy / Acid alpha-glucosidase / Clinical trial / ERT / Amyotrophic lateral sclerosis / Health / Medicine / Rare diseases


Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Add to Reading List

Document Date: 2011-12-11 11:39:13

Open Document

File Size: 35,91 KB

Share Result on Facebook

Company

Amicus Therapeutics / /

Country

United States / /

/

Event

FDA Phase / /

IndustryTerm

treatment of Fabry disease / biopharmaceutical / therapies for rare diseases / candidate drug products / therapy for Pompe disease / /

MedicalCondition

rare diseases / disease / lysosomal storage disorders / Fabry disease / diseases / lysosomal storage diseases / lysosomal storage disease / respiratory insufficiency / deficiency / Pompe disease / progressive skeletal muscle weakness / /

MedicalTreatment

Enzyme Replacement Therapy / /

Person

John F. Crowley / Pol F. Boudes / /

/

Position

Chief Medical Officer / Chairman and Chief Executive Officer / Private / /

Product

in / Amigal™ (migalastat HCl) / AT2220 / /

Technology

alpha / /

URL

www.pompestudy.com / www.clinicaltrials.gov / /

SocialTag